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Abstract: Lymph node involvement is the most important predictor of survival rates in 
patients with oral squamous cell carcinoma (OSCC). A biomarker that can indicate lymph 
node metastasis would be valuable to classify patients with OSCC for optimal treatment. In 
this study, we have performed a serum proteomic analysis of OSCC using 2-D gel 
electrophoresis and liquid chromatography/tandem mass spectrometry. One of the  
down-regulated proteins in OSCC was identified as tetranectin, which is a protein encoded 
by the CLEC3B gene (C-type lectin domain family 3, member B). We further tested the 
protein level in serum and saliva from patients with lymph-node metastatic and primary 
OSCC. Tetranectin was found significantly under-expressed in both serum and saliva of 
metastatic OSCC compared to primary OSCC. Our results suggest that serum or saliva 
tetranectin may serve as a potential biomarker for metastatic OSCC. Other candidate serum 
biomarkers for OSCC included superoxide dismutase, ficolin 2, CD-5 antigen-like protein, 
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RalA binding protein 1, plasma retinol-binding protein and transthyretin. Their clinical 
utility for OSCC detection remains to be further tested in cancer patients. 
Keywords: oral squamous cell carcinoma; serum proteomics; tetranectin; disease biomarker 
 
1. Introduction 
Oral cancer, predominantly oral squamous cell carcinoma (OSCC), is the sixth most common 
human cancer with an annual incidence of over 300,000 new cases worldwide [1,2]. The disease 
frequently metastasizes to the lymph nodes, which represents the most important predictor of patient 
survival rates. Typically, 50% of patients with OSCC have detectable lymph node involvement at 
presentation. Less than 40% of patients with lymph node metastasis at presentation survive five years, 
compared to ~90% of patients without metastasis [3,4,5]. In other words, the survival rate decreases by 
approximately 50% when nodal metastasis is present. Treatment of individuals clinically diagnosed 
with lymph node metastasis (N+) often involves a surgical procedure of radical neck dissection (RND) 
to remove a substantial portion of the neck. Upon histological examination of removed tissues, 
10−20% of clinically diagnosed N+ individuals turn out to be metastasis-free (N0) [6]. Clinical 
diagnosis of N0 status is even less accurate. Postoperative histological examination shows that 
approximately one-third of clinically diagnosed N0 individuals have metastasis-positive lymph nodes 
in the neck [7]. In fact, due to the low sensitivity of clinically detecting nodal metastasis and the poor 
prognosis when these metastases are missed, the current management of the clinically diagnosed N0 
neck commonly includes routine elective neck dissection (END) with pathologic examination of the 
removed lymph nodes [8]. END is less appropriate than RND for N+ individuals falsely diagnosed as 
N0 and, moreover, is completely unnecessary for individuals correctly diagnosed as N0. Although 
END is less rigorous than RND, the treatment causes disfigurement, long-term discomfort and pain 
and can lead to additional complications such as shoulder and neck disability [9]. 
To ensure optimal management of OSCC patients, there is a critical need for accurate staging of 
lymph nodes metastasis in the neck. Unfortunately, current preoperative clinical methods, including 
new radiographic techniques, are suboptimal and misdiagnose the presence or absence of cervical 
nodal metastasis in many patients [8]. Cancer biomarkers may be useful for prediction/detection of 
lymph-node metastasis in patients with OSCC. These biomarkers may help differentiate patients who 
clinically have no detectable disease but are potential candidates for lymph nodes metastasis and 
should have neck dissection and/or adjuvant radiotherapy. Conversely, the biomarkers would also help 
avoid unnecessary surgery treatment for metastasis-free patients. This notion was demonstrated in a 
quantitative PCR study to screen 40 potential markers for their ability to detect head and neck SCC 
(HNSCC) metastases to cervical lymph nodes. Four markers were able to discriminate between 
histologically positive and benign nodes with accuracy >97% and one marker, pemphigus vulgaris 
antigen, provided discrimination with 100% accuracy and correctly identified two lymph nodes with 
micrometastatic tumor deposits [10]. Many previous studies have also revealed proteins that promote 
the metastasis in oral/head and neck cancer (Table 1). Further validation of these proteins in metastatic 
and primary OSCCs may lead to valuable biomarkers for clinical staging of OSCC.  
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Table 1. A partial list of reported proteins promoting metastasis in HNSCC. 
Protein Up/Down Role in metastasis Reference 
Chemokine receptor 6 Down-regulation Controls immune cell trafficking in response to 
inflammatory stimuli 
[11] 
Endostatin & Collagen XVII Down-regulation Angiogenesis inhibitor [12] 
CD44 Down-regulation Cell adhesion molecule [13,14] 
Lin-7C/VELI3/MALS-3  Down-regulation Signals through β-catenin  [15] 
E-cadherin, β-catenin Down-regulation Adhesion molecule, reduction in cell-cell adhesion [14] 
Maspin Down-regulation Member of the serpin family of protease inhibitors [16] 
NM23-H1/NDPK  Down-regulation Metastasis suppressor factor [17,18] 
Nicotinamide N-
Methyltransferase (NNMT) 
Down-regulation Enzyme participating in nicotinate and 
nicotinamide metabolism 
[19] 
PAI-2  Down-regulation Inhibits conversion of plasminogen to plasmin and 
inhibit fibrolysis 
[20] 
Pemphigus vulgaris antigen Up-regulation Cell adhesion molecule [21] 
MMP-1, 2, 3, 9, MT1-MMP, 
TIMP-1 
Up-regulation Proteolytic activity against the components of ECM, 
MT1-MMP activates MMP-2, TIMP-1 inhibits 
MMP-2 
[22] 
Chemokine receptor 7  Up-regulation Mediator of immune cell survival and migration to 
lymph nodes 
[11,23] 
Cyclin D1 Up-regulation Cell cycle regulator [24,25] 
Cathepsin B & L Up-regulation Lysosomal proteolytic enzymes [26] 
Stefin A and B Up-regulation Inhibitors of cathepsin B and L [26] 
HIF-1 alpha Up-regulation Promotes tumor progression and metastasis [27] 
TWIST Up-regulation Essential mediator of cancer metastasis [27] 
PLC γ-1 Up-regulation Promotes tumor cell invasion when activated by 
EGFR 
[28,29] 
c-Src Up-regulation Proto-oncogene [28] 
EGFR & TGF-alpha Up-regulation Cell proliferation activator [30–32] 
pSTAT3 Up-regulation Transcription factor, regulates MMP-2 [24,31] 
SDF-1 alpha Up-regulation Promotes metastasis through activation of NF-
kappa B signaling 
[33] 
Met Up-regulation Increases MMP-9 [34] 
NBS1  Up-regulation Up-regulates Snail and MMP-2 [35] 
Integrin beta 6  Up-regulation Activates Fyn and promotes oral cancer 
progression 
[36] 
Cyclin B1 Up-regulation Cell cycle regulator [37] 
Erythropoietin (EPO) & EPO 
receptor 
Up-regulation Activates JAK-STAT signaling and cell invasion [38] 
FAK Up-regulation Cell differentiation and cell invasion [39] 
HER-2 & HER-3 Up-regulation Cell growth and differentiation [32,40] 
Integrin alpha v beta 6  Up-regulation Promotes tumor growth and invasion, activates 
MMP-3  
[41] 
VEGF & Interleukin 8 Up-regulation Promotes tumor angiogenesis, growth and 
metastasis 
[42] 
Hepatocyte growth factor 
(HGF) 
Up-regulation Induces the expression of Interleukin 8 and VEGF [43] 
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In this study, we have performed a serum proteomic analysis of OSCC using two-dimensional gel 
electrophoresis (2-DE) protein separation with liquid chromatography-tandem mass spectrometry  
(LC-MS/MS) for protein identification. One of the down-regulated proteins in OSCC patients’ sera 
was identified as tetranectin, which is a ubiquitously expressed lectin protein. This protein was 
previously found at reduced levels in patients with solid malignant tumors (breast, colon, and cervical 
cancer) [44–46]. We further measured the levels of tetranectin from patients with metastatic and 
primary OSCC, and both serum and saliva tetranectin was found significantly reduced in patients with 
metastatic OSCC.  
2. Materials and methods 
2.1. Patients and Samples 
In total, 34 OSCC and 10 healthy subjects were used in this study. Sixteen cancer patients were at 
early stage without lymph node metastasis (N = 0) whereas the other 18 patients had lymph-node 
metastasis (N+). All patients provided consent according to the institutional review board of University 
of California, Los Angeles. Patients did not receive any treatment prior to serum or saliva collection. 
Standardized protocol was used for collection, storage, and processing of the serum and saliva 
samples, as described previously [47,48]. The samples were aliquoted and stored at −80 °C.  
2.2. 2-D Gel Electrophoresis 
Serum samples from 10 OSCCs and 10 matched control subjects were used for 2-DE analysis. 
There were no significant differences in terms of mean age, gender or smoking history (p > 0.75). All 
the serum samples were precipitated by rapid adding four times volume of cold acetone containing 
10% (w/v) trichloroacetic acid (TCA). The mixture was kept at −20 °C overnight and centrifuged at 
13,200 g, 4 °C, for 15 minutes. The pellet was then washed with cold acetone followed by 
centrifugation at 13,200 g, 4 °C for 15 minutes. The sample pretreatment step helped remove most of 
albumin from serum/plasma samples [49]. After removing the supernatant, the pellet was dissolved in 
rehydration buffer and stored at −80 °C prior to 2-DE analysis. Protein assay was performed using the  
2-D Quant Kit (Amersham).  
A total of 20 protein samples (10 OSCC and 10 control, 150 μg proteins each sample) were 
individually mapped out using 2-DE. Isoelectric focusing (IEF) was performed using the immobilized 
pH gradient (IPG) strips (17-cm length, pI 3-10 NL) on a Protean IEF cell, and SDS-PAGE was 
performed with the 8–16% precast Protean II gels (Bio-Rad). Proteins were visualized with the 
fluorescent Sypro-Ruby staining (Molecular Probes). 
Analysis of the 2-D gel images was performed using the PDQuest (Bio-Rad). A matchset was 
created initially, and protein spots were automatically matched and further verified. Afterwards, 
normalization was performed based on the total density of the gel image and the levels of proteins 
were quantified.  
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2.3. LC-MS/MS and Database Searching 
Protein spots of interest were excised using a spot-excision robot (Proteome Works, Bio-Rad) and 
deposited into 96-well plates. Proteins in gel spots were reduced with 10 mM DTT for 30 min, 
followed by alkylation with 50 mM iodoacetamide for 60 min in the dark, and then digested with  
10-ng trypsin at 37 °C overnight. After digestion, all the samples were dried and re-constituted with 
0.1% formic acid for subsequent LC-MS/MS analysis.  
LC-MS/MS was performed using a LC Packings nano-LC system (Sunnyvale, CA, USA) with a 
nanoelectrospray interface (Protana, Odense, Denmark) and quadrupole time-of-flight (Q-TOF) mass 
spectrometer (Applied Biosystems, QSTAR XL, Foster City, CA, USA). A New Objective (Woburn, 
MA, USA) PicoTip tip (I. D., 8 mm) was used for spraying with the voltage at 1850 V for online MS 
and MS/MS analyses. Nano-LC separation of peptides was performed with home-made C18 
precolumns (300 μm × 1 mm; particle size 5 μm) and LC Packings PepMap C18 columns  
(75 μm × 150 mm; particle size 5 μm) at a flow rate of 250 nL/min. The eluents used for the LC were 
(A) 5% ACN/95% H2O/0.1% FA and (B) 95% ACN/5% H2O/0.1% FA. A gradient was utilized from 
5% B to 60% B in 55 min, and ramped to 95% B in 0.1 min. After 5 min at 95% B, the column was  
re-equilibrated for 15 min before the next run. 
Database searching was performed against the EBI human IPI database (version 3.03) using the 
Mascot database search engine (version 2.1, Matrix Science, London, UK). One missed tryptic 
cleavage was allowed, and a mass tolerance of 0.3 Da was set for the precursor and product ions. A 
Mascot score of >40 with a p-value < 0.05 was considered a significant match of a peptide. The 
MS/MS spectra for each peptide were manually examined to verify the identification. 
2.4. Western Blot Analysis 
Western blotting was used to measure the level of tetranectin in a new set of OSCC serum samples 
(12 primary/12 metastatic OSCC). Proteins were separated on 12% SDS-PAGE gels at 150 V for about 
one hour and then transferred to polyvinylidene difluoride membrane using a Mini Trans-Blot 
electrophoretic transfer cell (Bio-Rad). After saturating with 5% milk in TBST buffer overnight at  
4 °C, the blots were sequentially incubated with primary antibody (Lab Vision, 1:250 dilution) and 
horseradish peroxidase-conjugated antimouse IgG secondary antibody (Amersham, 1:5000 dilution). 
Finally, the bands were visualized by enhanced chemiluminescence detection (Amersham). Tetranectin 
was also validated in the saliva samples of 12 primary and 12 metastatic OSCCs. The level of 
tetranectin was normalized against actin for quantification, and p values were determined using the 
student’s T-test. 
3. Results 
Instead of analyzing pooled samples from patient or control groups, we individually mapped out 
serum proteins from 10 OSCC patient samples and 10 matched controls with 2-DE. Figure 1A shows 
representative 2-D gel patterns of serum proteins from OSCC and healthy subjects. With initial 
normalization of the spot intensities and subsequent statistical t-test analysis, 32 protein spots were 
found with significantly different abundances between the OSCC and control groups (p < 0.05), 
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including 18 up-regulated and 20 down-regulated ones in OSCC. A list of these up- or down-regulated 
serum proteins identified by LC-MS/MS is shown in Table 2.  
Figure 1B shows the level of tetranectin among the 10 OSCC and 10 healthy control subjects based 
on 2-DE analysis. The protein was significantly down-regulated in OSCC patients compared to the 
healthy control subjects. Figure 1C depicts the tandem MS spectrum for a doubly charged tryptic 
peptide (m/z 697.4), LDTLAQEVALLK, originated from tetranectin. The precursor ion was well 
fragmented to yield sufficient structural information to identify the peptide sequence based on Mascot 
database searching. In total, 8 peptides derived from tetranectin were identified, resulting in an overall 
sequence coverage of 32%. Conversely, both isoforms of serum amyloid A-4 (SAA-4) were  
up-regulated in patients with OSCC (Figure 2).  
Using Western blot analysis, we tested the level of tetranectin in an independent set of primary and 
metastatic OSCC patients (Figure 3). Tetranectin was found significantly under-expressed in serum  
(p = 0.03) and saliva (p = 0.007) of metastatic OSCC compared to primary OSCC. Besides, the level 
of tetranectin was further confirmed by Western blotting on a set of OSCC and control serum samples 
(n = 25 for each group). The protein level was found to be significantly lower (p = 0.004) in OSCC 
than in healthy control samples, which agrees to the result obtained by 2-DE. 
Figure 1. Analysis of serum proteins from OSCC and healthy control subjects using 2-DE 
with tandem MS. (A) 2-DE separation of serum proteins. 1st-dimension separation: IEF, 
IPG strips (pI 3-10, non-linear. 2nd-dimension: SDS-PAGE, 18-cm 8–16% gradient gels. 
The proteins were visualized using Sypro Ruby staining; (B) Serum tetranectin (circled) 
was found at significantly reduced level in OSCCs (n = 10) compared to healthy controls 
(n = 10), based on 2-DE analysis; (C) ESI-MS/MS spectrum of a tryptic peptide, 
LDTLAQEVALLK, originated from tetranectin. The protein was identified by using in-gel 
digestion and LC-MS/MS analysis of the resulting peptides.  
 
(A) 
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Figure 1. Cont. 
 
 
 
Figure 2. Serum amyloid A-4 protein (SAA-4) is significantly over-expressed in OSCC 
compared to healthy individuals. (A) Both isoforms of SAA-4 were found significantly 
higher in OSCC than healthy controls, based on 2-DE analysis; (B) The ESI-MS/MS 
spectrum for a tryptic peptide, EALQGVGDMGR, derived from SAA-4. 
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Figure 2. Cont. 
100 200 300 400 500 600 700 800 900 1000 1100
m/z, amu
0
10
20
30
40
50
Intensity, counts
y5
551.2b2
201.1
b4*++
242.1 y7
707.3
643.3b10++
487.2296.2
y8*++
409.2a2
173.1 y3
379.2 y*8
818.3y4
494.2
b3
314.2
y8
835.4
b*8
754.3b1
130.0
586.3 y9
948.5
y6
650.3
b4
442.2
y7*++
268.2
Intensity, counts
 
Figure 3. (A) Western blot analysis of tetranectin in serum samples from primary (n = 12) 
and lymph-node metastatic (n = 12) OSCC subjects; (B) Western blotting of tetranectin in 
saliva samples from primary OSCC (n = 12) and lymph-node metastatic OSCC (n = 12). 
The bar figures show the normalized level (y-axis) of tetranectin against actin. Tetranectin 
was significantly under-expressed in metastatic versus primary cancer (Serum: p = 0.03; 
saliva: p = 0.007). 
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Table 2. A list of identified serum proteins with significantly different abundances 
between the oral cancer and control subjects. 
Accession Protein Name 
Isoelectric 
Point 
Molecular 
Weight 
Peptides 
Identified 
P 
Value 
Ratio 
(ctrl/cancer) 
IPI00332128 48 kD Protein 5 48396 2 0.021 0.28 
IPI00384697 ALB protein 5.97 47330 8 0.048 1.72 
IPI00022429 Alpha-1-acid glycoprotein 1 5.11 24770 13 0.030 1.99 
IPI00020091 Alpha-1-acid glycoprotein 2 5.03 23588 2 0.029 1.59 
IPI00305457 Alpha-1-antitrypsin 5.19 48208 12 0.018 0.47 
IPI00021842 Apolipoprotein E 5.65 36132 6 0.040 1.85 
IPI00177869 Apolipoprotein L1 Isoform A 5.6 43947 2 0.015 1.68 
IPI00025204 CD-5 Antigen like protein 5.28 38063 7 0.029 1.59 
IPI00164623 Complement C3 fragment 6.02 187046 4 0.022 0.00 
IPI00027827 Extracellular superoxide 
dismutase 
6.14 25865 2 0.031 0.27 
IPI00017530 Ficolin 2 6.09 33998 2 0.019 0.65 
IPI00478493 Haptoglobin 6.13 45177 10 0.041 0.35 
IPI00296170 Haptoglobin-related protein 6.42 43049 2 0.003 2.00 
IPI00477597 Haptoglobin-related protein 6.42 38983 5 0.012 5.59 
IPI00431645 HP protein 8.48 31362 4 0.006 0.55 
IPI00472610 Hypothetical protein 7.5 52633 10 0.013 2.32 
IPI00332161 Ig gamma 1 Chain C region 8.46 36083 8 0.020 0.41 
IPI00385058 Ig kappa chain C region 7.51 26283 4 0.031 1.81 
IPI00335356 Ig mu chain C region 6.35 49526 8 0.029 0.31 
IPI00022420 Plasma retinol-binding protein 5.76 23029 5 0.024 2.55 
IPI00009544 RalA binding protein 1 5.68 76016 2 0.008 1.84 
IPI00009544 RalA binding protein 1 5.68 76016 2 0.034 1.73 
IPI00019399 Serum Amyloid A-4 protein 
isoform 1 
9.27 14797 2 0.044 0.37 
IPI00019399 Serum amyloid A-4 protein 
isoform 2 
9.27 14797 3 0.038 0.58 
IPI00550061 Similar to Ig gamma 3 Chain 
C region 
7.47 56823 6 0.032 1.67 
IPI00221125 Voltage-gated potassium 
channel beta-1 subunit 
9.23 45462 4 0.006 1.79 
IPI00009028 Tetranectin 5.52 22552 7 0.045 1.84 
IPI00009028 Tetranectin 5.52 22552 8 0.030 1.68 
IPI00022432 Transthyretin 5.52 15877 16 0.022 1.45 
IPI00022432 Transthyretin 5.52 15877 7 0.040 3.76 
4. Discussion 
Our study suggests that tetranectin is a potential biomarker for metastatic OSCC because tetranectin 
in both serum and saliva is significantly reduced in metastatic OSCC compared to primary OSCC. 
Tetranectin belongs to a distinct group of the C-type lectin superfamily. In fact, human tetranectin is a 
homotrimer forming a triple alpha-helical coiled coil. Each monomer consists of a C-type lectin 
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domain (i.e., carbohydrate recognition domain) connected to a long alpha helix [50]. Tetranectin binds 
specifically to the kringle 4 domain of plasminogen, which is a circulating zymogen [51]. For several 
decades, it has been postulated that plasminogen activation plays an important role in tumor invasion 
and metastasis. Plasminogen activators released from cancer cells may catalyze the proteolytic 
conversion of the inactive zymogen plasminogen to the active protease plasmin, which in turn 
catalyzes degradation of proteins in basement membranes and extracellular matrix (ECM) and thus 
facilitates cancer cell invasion into the surrounding tissue. There are two types of plasminogen 
activators (PA), the urokinase-type (uPA) and the tissue-type (tPA). uPA is generally agreed to be the 
enzyme of most relevance to tumor biology, while the primary role of tPA is generation of plasmin for 
fibrinolysis in blood vessels. Several other proteins, fibrin, uPA receptor (uPAR), and two main PA 
inhibitors, PAI-1 and PAI-2, are also important in this process. Fibrin is a cofactor for plasminogen 
activation by tPA whereas uPAR (cell membrane-anchored uPA binding protein) is a cofactor for 
plasminogen activation by uPA [52]. Besides plasminogen, tetranectin also specifically binds to the 
plasminogen-like hepatocyte growth factor and tPA, in a calcium dependent way, but does not interact 
with uPA. The enhanced activation was suggested to be caused by tetranectin's ability to bind and 
accumulate tPA in an active conformation [53]. PAI-1 and PAI-2 belong to the serine protease 
inhibitor super-family and are involved in the regulation and inhibition of binding between uPA and its 
receptor. PAI-2 has been identified as a potential biomarker for invasive HNSCC, since PAI-2 
expression at both mRNA and protein levels decreased dramatically in cultured HNSCC cells as well 
as in HNSCC biopsy specimens when invasion into the underlying connective stroma occurred [20].  
Tetranectin was initially implicated as a cancer biomarker because decreased plasma levels of 
tetranectin correlated with cancer progression [46,54]. In the case of ovarian cancer, decreased plasma 
levels of tetranectin were found as a stronger predictor of adverse prognosis than cancer stage [55]. 
Low levels of serum tetranectin also correlated with poor treatment responses in patients with 
metastatic breast cancer [45,46]. These results, including ours about OSCC, corroborate that 
tetranectin may be used as a marker for metastasis and classification of patients with solid tumor of 
epithelial origin.  
Although the precise biological function of tetranectin in tumorigenesis is unknown, the protein 
likely has a role in cancer progression by enabling tumour cell invasion and metastasis through 
activation of the plasminogen-cascade and enhancement of the proteolytic processes. By binding to 
plasminogen, tetranectin may enhance activation of plasminogen to plasmin, which plays a role in the 
degradation of extracellular proteins and cancer progression. Tetranectin is present in the stroma of 
breast, ovary, colon cancers but not present in corresponding normal tissue [56,57]. Based on 
immunohistochemistry (IHC) studies, tetranectin was found in a fibrillar-like pattern in the ECM 
around the tumour islands but not detectable in the normal colon stromal tissue. These observations 
suggest that tetranectin may be produced locally by cells of the stromal compartment of tumours and 
then deposited into the ECM. In addition, tetranectin exhibited a similar IHC staining pattern as 
plasminogen in colon cancer and co-localized with plasminogen/plasmin at the invasive front of 
cutaneous melanoma lesions, indicating a coordinated role of these proteins in the invasive process 
[57,58]. Positive staining for tetranectin in cancer stroma also strongly correlated with cancer 
progression [55,59]. 
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The differential level of saliva tetranectin between metastatic and primary OSCC appeared to be 
more significant than that of serum tetranectin. Oral cancer cells are immersed in the salivary milieu. 
Tetranectin seems to be consumed in the tumour microenvironment where proteolytic activity is 
needed for tumour metastasis, and therefore less amount of tetranectin is present in saliva of patients 
with metastatic tumour than primary tumour. Nevertheless, saliva is an easily accessible body fluid 
that can be used for survey of the general health and diagnosis of human diseases [60–63]. Salivary 
testing provides several key advantages including low cost, non-invasiveness, and easy sample 
collection, especially under circumstances when it is difficult to obtain blood samples. In fact, 
comparisons between the proteomes of plasma and saliva have indicated that a number of proteins 
found in saliva are present in blood [64,65]. Testing of protein biomarkers such as tetranectin in saliva 
from patients with OSCC may be useful for classification of OSCC patients.  
5. Conclusion 
In summary, we have demonstrated that serum proteomics is a valuable approach to discovery of 
protein biomarkers for oral cancer. Besides tetranectin, this study also revealed candidate biomarkers 
such as SAA-4, superoxide dismutase, ficolin 2, CD-5 antigen-like protein, plasma retinol-binding 
protein, RalA binding protein 1 and transthyretin that may have diagnostic value for OSCC. SAA was 
confirmed as a prognostic biomarker for myeloma in a recent study. SAA combined with C reactive 
protein might be used as prognostic serological biomarkers in early-stage melanoma patients, helping 
to discriminate low-risk patients from high-risk patients needing adjuvant treatment [66]. Further 
studies are needed to enroll additional patients aimed to validate these potential biomarkers including 
tetranectin. If successfully validated, protein biomarkers such as tetranectin may be used to classify 
patients with lymph node metastasis for appropriate treatment.  
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